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Leptin is a versatile 16 kDa peptide hormone, with a tertiary
structure resembling that of members of the long-chain helical
cytokine family. It is mainly produced by adipocytes in proportion
to fat size stores, and was originally thought to act only as a
satiety factor. However, the ubiquitous distribution of OB-R leptin
receptors in almost all tissues underlies the pleiotropism of
leptin. OB-Rs belong to the class I cytokine receptor family, which
is known to act through JAKs (Janus kinases) and STATs (signal
transducers and activators of transcription). The OB-R gene is
alternatively spliced to produce at least five isoforms. The full-
length isoform, OB-Rb, contains intracellular motifs required for
activation of the JAK/STAT signal transduction pathway, and is
considered to be the functional receptor. Considerable evidence
for systemic effects of leptin on body mass control, reproduction,
angiogenesis, immunity, wound healing, bone remodelling and
cardiovascular function, as well as on specific metabolic path-
ways, indicates that leptin operates both directly and indirectly
to orchestrate complex pathophysiological processes. Consistent
with leptin’s pleiotropic role, its participation in and cross-
talk with some of the main signalling pathways, including those
involving insulin receptor substrates, phosphoinositide 3-kinase,
protein kinase B, protein kinase C, extracellular-signal-regulated
kinase, mitogen-activated protein kinases, phosphodiesterase,
phospholipase C and nitric oxide, has been observed. The impact
of leptin on several equally relevant signalling pathways extends
also to Rho family GTPases in relation to the actin cytoskeleton,
production of reactive oxygen species, stimulation of prostag-
landins, binding to diacylglycerol kinase and catecholamine
secretion, among others.
Key words: adipocyte, cytokine, Janus kinase/signal transducer
and activator of transcription pathway (JAK/STAT pathway),
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INTRODUCTION
The discovery of leptin at the end of 1994 [1] opened up a whole
new perspective to study the role of adipocyte-derived factors in
energy balance homoeostasis [2–7]. The 16 kDa non-glycosylated
polypeptide product of the ob gene is mainly produced and
secreted by fat cells in proportion to fat mass to signal the repletion
of body energy stores to the hypothalamus [7–11]. Leptin presents
striking structural similarities to members of the long-chain
helical cytokine family, including LIF (leukaemia inhibitory
factor), CNTF (ciliary neurotrophic factor), OSM (oncostatin-M)
and CT-1 (cardiotrophin-1), as well as IL-6 (interleukin-6),
IL-11 and IL-12 [8,12–15]. Both the crystal structure and NMR
studies of leptin have revealed that the protein adopts a cytokine
fold similar to that exhibited by the short-helix subfamily of
cytokine folds [13,15]. The three-dimensional structure of the
167-amino-acid leptin molecule is based on four antiparallel
α-helices, connected by two long crossover links and one short
loop arranged in a left-handed helical bundle, which forms a two-
layer packing. A disulphide bond between two cysteine residues
(Cys96 and Cys146) of the C-terminus of leptin and the beginning
of one of the loops has been shown to be important for structure
folding and receptor binding, as mutation of either of the cysteine
residues renders the protein biologically inactive [8,12–15].
Circulating leptin concentrations have been reported to cor-
relate closely with both the BMI (body mass index) and the total
amount of body fat [7–9]. Although leptin is mainly produced
and secreted to the bloodstream by white adipocytes, this is not
the only potential source of the hormone. Placenta, gastric mu-
cosa, bone marrow, mammary epithelium, skeletal muscle, pitu-
itary, hypothalamus and bone have also been shown to be able
to produce small amounts of leptin in certain circumstances
[16–19]. Initially, the effects of leptin were thought to be only
centrally mediated. However, leptin shares with other members
of the long-chain helical cytokine family an extreme functional
pleiotropy. Although originally isolated in relation to a particular
biological action, many cytokines have subsequently been
shown to be capable of stimulating a variety of biological re-
sponses in a wide spectrum of cell types. Based on an almost
ubiquitous distribution of receptors, leptin has been reported to
play a role in a quite diverse range of physiological functions
both in the central nervous system and at the periphery [9,20–24].
Therefore, since its discovery, leptin has caused upheavals not
only in the fields of appetite and body mass control, but also in
the more broad spheres of general endocrinology, metabolism,
reproduction, immunology, cardiovascular pathophysiology,
respiratory function and wound healing, as well as in growth and
development [25–48]. In this sense, completely disentangling the
biochemical and molecular pathways activated by leptin repre-
sents a fascinating challenge.
BINDING PROTEINS AND CLEARANCE
In humans, the majority of leptin circulates bound to serum
macromolecules, which may modulate ligand bioactivity and
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bioavailability to target tissues [49]. In lean subjects with a rel-
atively small adipose tissue mass, the majority of leptin is in
the bound form, while the proportion of free leptin is increased
in the serum of obese patients [49,50]. Free leptin may have
a more rapid turnover because of proteolytic cleavage or in-
creased clearance. During fasting, a decrease in free leptin con-
centrations has been observed, which is more pronounced in lean
volunteers compared with obese subjects, whereas no change was
observed in bound leptin in either group [50]. It may be specu-
lated that the ratio of free/total leptin is not constant, but rather
that, depending on the metabolic and nutritional state, a dynamic
balance between circulating binding proteins and free leptin
exists. A precedent for the key role played by binding proteins
in the transport or uptake of ligands has been shown for other
members of the cytokine family. Moreover, for some cytokines
and haematopoietic growth factors, association with binding pro-
teins potentiates ligand activity because of biochemical modifi-
cations [51]. These phenomena provide a potential explanation
for apparent leptin resistance in the setting of increased free
leptin concentrations. The short half life of leptin in the circu-
lation is determined mainly by efficient renal clearance by a high-
capacity non-saturable process, consistent with glomerular
filtration, followed by metabolic degradation in the renal tubules
[52,53].
LEPTIN RECEPTORS
The pleiotropic nature of leptin is supported by the universal
distribution of OB-R leptin receptors. Leptin acts via trans-
membrane receptors, which show structural similarity to the
class I cytokine receptor family [54–58], which includes the re-
ceptors of IL-2, IL-3, IL-4, IL-6, IL-7, LIF, granulocyte colony-
stimulating factor, growth hormone, prolactin and erythropoietin
[59,60]. Members of this family have characteristic extracellular
motifs of four cysteine residues and WSXWS (Trp-Ser-Xaa-Trp-
Ser) [61] containing a different number of fibronectin type III
domains [62,63]. The OB-R is produced in several alternatively
spliced forms, designated OB-Ra, OB-Rb, OB-Rc, OB-Rd,
OB-Re and OB-Rf [55,64], that have in common an extracellular
domain of over 800 amino acids, a transmembrane domain of
34 amino acids and a variable intracellular domain, characteristic
for each of the isoforms. Thus the isoforms can be classified into
three classes: short, long and secreted. In addition to containing
identical extracellular and transmembrane domains, the short and
long isoforms share the same first 29 intracellular amino acids,
diverging in sequence secondary to alternative splicing of 3′ exons.
The extracellular domain of OB-R has two cytokine-like receptor
motifs and four fibronectin type III domains [54,57,58,65]. Mutant
receptor constructs have shown that only the second putative
binding domain mediates leptin binding and receptor activation,
with an affinity which lies in the nanomolar range [66]. The short
forms of the receptor, i.e. OB-Ra, OB-Rc, OB-Rd and OB-Rf,
consist of 30–40 cytoplasmic residues. However, only the long
full-length isoform, OB-Rb, was initially considered to be the
functional receptor, based on the finding that it has an extended
intracellular domain of approx. 300 cytoplasmic residues (longer
in humans than in mouse), containing various motifs required
for the interaction with other proteins and subsequent signalling
pathway activation [54].
The lack of the full-length OB-R has been shown to be
responsible for the obesity phenotypes of the db/db mouse and the
fa/fa rat [67]. Selective deletion of all OB-R isoforms in neurons
has been shown to lead to obesity in mice, providing evidence for
the relevance of neuronal leptin action in body mass regulation
[68]. OB-Rb has been found to be expressed at high levels in the
hypothalamus. OB-Ra and OB-Rc are highly expressed in choroid
plexus and microvessels, where they may play a role in leptin
uptake or efflux from the cerebrospinal fluid as well as in receptor-
mediated transport of leptin across the blood–brain barrier
[24,69]. OB-Re, which lacks the intracellular domain, may encode
a soluble receptor [55]. The secreted isoform, OB-Re, represents
an alternative splice product or proteolytic cleavage products
of membrane-bound OB-R. Secreted extracellular domains of
cytokine receptors have been shown to function as specific binding
proteins [51]. In mice, it has been reported that the putative soluble
isoform, OB-Re, is produced at a sufficiently high level to act as a
buffering system for free circulating leptin [56]. It has been shown
that the soluble OB-R represents the main leptin-binding activity
in human blood [70] and that it is determined by sex, adiposity
and leptin administration [71]. Consistent with leptin’s role in con-
trolling appetite and energy metabolism, OB-Rs have been found
in the hypothalamus and adjacent brain regions [54,57]. Initially,
direct actions of leptin were thought to be circumscribed only
to the central nervous system. However, the almost universal
distribution of OB-Ra and OB-Rb reflects the multiplicity of
biological effects in extraneural tissues, providing evidence for
the extreme functional pleiotropy of leptin.
RECEPTOR INTERNALIZATION
Cytokine receptor family members are known to be internalized
upon ligand binding via clathrin-coated vesicles into early endo-
somes, with the receptor being processed for degradation or
efficiently recycled back to the cell surface (Figure 1) [72].
It has been estimated that, under normal conditions, only 5–
25% of the total OB-R isoforms are located at the cell
surface, with the majority contained in intracellular pools [73].
Both OB-Ra and OB-Rb mediate lysosomal internalization
and degradation, with amino acids 8–29 of the intracellular
domain determining the process [72,74]. It has been reported by
some authors that leptin internalization and down-regulation of
surface receptors is greater for OB-Rb [73]. Additionally, the
short receptor isoform has been shown to recycle to the cell
surface faster [74]. Taken together, these observations provide
a plausible explanation for selective leptin resistance linked
to hyperleptinaemia in human obesity based on a preferential
down-regulation of OB-Rb signalling. Although in vitro studies
with transfected OB-R have shown the existence of a large
intracellular receptor pool [72–74], the functional meaning of
this distribution and the exact in vivo trafficking dynamics
have not been fully established. Determination of the cellular
mechanisms underlying these processes represents a critical
step towards a better understanding of the intracellular traffic,
the control of the residence time of receptors at the cell sur-
face, and hence the potential relationship to leptin sensitivity.
Both OB-R isoforms have been reported to be short-lived
membrane proteins and to follow similar intracellular routes,
despite showing structural and functional differences in their
cytoplasmic domains [75]. Based on indirect pieces of evidence
regarding high turnover rates, levels of recycling pathway markers
and stability of endocytosed receptors in response to chloroquine,
this study did not support the recycling of OB-R to the cell sur-
face. Furthermore, it suggested that a fraction of neosynthesized
OB-R is transported to the plasma membrane, before being
constitutively endocytosed and degraded in lysosomes, while
another fraction is retained inside the cell, and could possibly
follow an alternative pathway leading to lysosomes without prior
access to the cell surface [75]. Whether the relative levels of
the intracellular and cell-surface pools of OB-R might be modu-
lated in response to physiological stimuli, as well as the potential
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Figure 1 Leptin receptor internalization
Schematic representation of lysosomal internalization and degradation of leptin receptors via clathrin-coated vesicles.
contribution of regulatory defects in this process to leptin sensiti-
vity, remain to be established.
MAIN SIGNALLING PATHWAYS
During the last few years, the study of the signalling events
derived from leptin binding to its receptor has promoted a better
understanding of the biochemical and molecular mechanisms of
leptin function. The homology of OB-R with other class I cytokine
receptors, such as the gp130 (glycoprotein 130) subunit of the
IL-6 receptor family, suggested the possibility that leptin binding
might mediate cytokine receptor-like signals, including the activ-
ation of JAKs (Janus kinases) and STATs (signal transducers and
activators of transcription) [76–78]. Therefore, although leptin
and its receptors were discovered relatively recently, a great deal
was already known about the molecular details of class I cytokine
receptor-mediated signalling and physiological regulation. Thus
early recognition of OB-R as a member of this cytokine receptor
superfamily resulted in the prompt identification of the JAK/STAT
pathway as one of the main signalling cascades activated by
leptin [45,60,72,79]. Subsequent studies showed that only the
full-length isoform, OB-Rb, contains intracellular motifs required
for activation of the JAK/STAT signal transduction pathway
[24,58,80]. Chimaeric receptor heterodimers of OB-Ra and
OB-Rb failed to activate the JAK/STAT pathway, whereas dimers
of OB-Rb gave rise to the expected ligand-dependent activation of
JAK [81]. Furthermore, deletion and substitution mutagenesis
experiments of the intracellular domain of OB-Rb have shown that
ligand-independent homo-oligomerization by the long isoform is
sensitive to reduction in JAK recruitment capability, suggesting
that JAK interaction and signalling competency may provide
means for specific OB-R sorting [82].
JAK/STAT signal transduction cascade
The JAK/STAT pathway comprises a family of four non-receptor
tyrosine kinases (JAKs) and seven 85–95 kDa transcription factors
(STATs) that are regulated by phosphorylation on specific serine
and tyrosine residues. Typically, the JAK/STAT signal transduc-
tion cascade is activated by interferons, interleukins or other
cytokines whose receptors lack intrinsic kinase activity. Func-
tional cytokine receptors contain a proline-rich ‘box1’ motif that
is required for JAK interaction and activation [83]. Furthermore,
less-well-conserved sequences, termed ‘box2’ also play a role
in JAK interactions and isoform selectivity. Of the four known
members of the JAK family, JAK1, JAK2 and TYK2 (tyrosine
kinase 2) are widely expressed, while JAK3 is found only in
cells of the haematopoietic immune systems [84]. The OB-R
does not have an intrinsic tyrosine kinase domain, and therefore
binds cytoplasmic kinases, mainly JAK2 [85]. Box1 and box2
motifs are known to recruit and bind JAKs [86,87]. However,
for leptin signalling, it was reported that only box1 and the
immediate surrounding amino acids are essential for JAK activ-
ation [81,88]. Box1 and amino acids 31–36 of the intracellular do-
main have been proved to be indispensable for this interaction,
while amino acids 37–48 seem to be involved in increasing the
signal, but can be replaced by other elements [88]. The intra-
cellular domain of all OB-R isoforms contains in the juxta-
membrane region the box1 JAK-binding domain, whereas OB-Rb
also includes the box2 motif and STAT-binding sites. Although
only OB-Rb was initially viewed as the isoform with signalling
capacity, the short isoforms have also demonstrated divergent
signalling capacities [89–93]. Both long and short receptor
isoforms have the ability of homodimer formation in the absence
of a ligand, with the extent of this association not being signifi-
cantly changed by ligand stimulation, suggesting that dimeriz-
ation does not play a key regulatory role in receptor activation [94–
96]. However, dimer formation appears to be actively involved in
post-receptor signalling [66,97]. A 1:1 stoichiometric relationship
between OB-R and leptin results in a tetrameric receptor–ligand
complex [96]. The conformational change in the structure of the
receptor elicited by the complex formation has been reported to
be critical for leptin signalling activation [60]. In the absence of
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Figure 2 Role of phosphotyrosines of OB-Rb in leptin signalling
JAK2 associates with the receptor via the box1 motif. The long isoform leptin (L) receptor (OB-Rb) contains four important tyrosine residues (Tyr974, Tyr985, Tyr1077 and Tyr1138). These phosphorylated
tyrosine residues provide docking sites for signalling proteins with SH2 domains. Most importantly, Tyr1138 recruits the transcription factor STAT3, which is subsequently phosphorylated by JAK2,
dimerizes and translocates to the nucleus, where it induces SOCS3 and POMC (pro-opiomelanocortin) expression, while repressing AgRP (agouti-related peptide). SOCS proteins inhibit signalling
by binding to phosphorylated JAK proteins or interacting directly with tyrosine-phosphorylated receptors. The ability of SOCS3 to inhibit leptin-stimulated phosphorylation of JAK2 and ERK provides
a negative-feedback mechanism on the leptin signalling system. Grb-2, growth factor receptor binding-2.
ligand, no OB-R heterodimers have been observed; these become
readily detectable in the presence of leptin [82,96]. Contrary to
what takes place with other class I cytokine receptors, leptin does
not undergo heterodimerization with structurally similar cytokine
receptors, as is the case with IL-6, IL-11, LIF, CT-1, CNTF or
OSM [72,95].
The expression of chimaeric receptors containing the extra-
cellular ligand-binding domain of the erythropoeitin receptor
fused to the transmembrane and intracellular domains of the long
OB-R isoform allowed the demonstration that the intracellular
domain activated JAK2, but not JAK1 or TYK2 [57,58,88,96]. In
addition to box1 sequences, intracellular residues 31–36 of OB-
Rb were shown to be required for JAK2 activation [88]. However,
high-level overexpression of JAKs by transient transfection has
been observed to be able to decrease the stringency of the require-
ment for residues 31–36 [58,88]. This finding is consistent with the
observation of weak OB-Rb–JAK1- and OB-Ra–JAK2-induced
signalling under transient transfection conditions [80]. It can
be concluded that box1 is absolutely necessary for all cytokine
receptor–JAK interactions, with residues homologous with intra-
cellular amino acids 31–36 of OB-Rb determining the specificity
of JAKs interacting with a particular receptor [58].
Since OB-Rb does not have intrinsic enzymatic activity, it
signals by activating non-covalently associated JAK2, which auto-
phosphorylates numerous tyrosine residues at the same time as
it phosphorylates tyrosine residues on the functional leptin re-
ceptor. JAK2 proteins are associated with membrane-proximal
sequences of the receptor intracellular domain, which is phos-
phorylated upon ligand binding. The phosphorylated intracellular
domain then provides a binding site for STAT proteins, which are
activated, translocate to the nucleus and stimulate transcription
(Figures 2 and 3). Ligand–receptor binding activation of STAT3,
STAT5 and STAT6, but not STAT1, STAT2 or STAT4, has been
described in relation to OB-R [72]. Furthermore, the SHP-2
[SH2 (Src-like homology 2) domain-containing protein tyrosine
phosphatase] has been demonstrated to bind to a phospho-
tyrosine of the intracellular domain of OB-R with the ability to
down-regulate tyrosine phosphorylation-dependent leptin signall-
ing such as STAT3 activation.
To determine the role of the three intracellular tyrosine res-
idues (Tyr985, Tyr1077 and Tyr1138), researchers created constructs
replacing either one of the three tyrosine residues or combinations
of them [98,99]. It has been shown that all three intracellular
tyrosine residues of OB-Rb exhibit different capabilities for down-
stream activation signalling. Tyr985 is required for the activation
of the Ras/Raf/ERK (extracellular-signal-regulated kinase) path-
way. The phosphorylation of Tyr985 creates a binding site for the
C-terminal SH2 domain of the tyrosine phosphatase SHP-2, lead-
ing to the activation of the canonical p21Rasρ /ERK signalling cas-
cade. The canonical mechanism by which tyrosine kinases activate
ERK is through the SH2-domain-containing adapter protein,
Grb-2 (growth factor receptor binding-2) [58]. Although Tyr985
mediates the majority of ERK stimulation, leptin-stimulated ERK
activation is also regulated, in part, independently of OB-Rb
phosphorylation, most probably via tyrosine phosphorylation
sites on JAK2 [24,100–102]. Tyrosine phosphorylation of SHP-2
before STAT3 dimerization has been clearly shown to play a
pivotal role in leptin-induced stimulation of ERKs [101,102].
However, in macrophages, it has been also reported that STAT3
can be phosphorylated at Ser727 [103]. Furthermore, in these
cells, ERK-dependent serine phosphorylation was required for
maximal activation of STAT3 DNA binding, providing evidence
that this intracellular signalling mechanism is likely to be a
relevant pathway in exerting the effects of leptin in relation to
immune function.
While either Tyr1077 or Tyr1138 is required for leptin-induced
tyrosine phosphorylation of STAT5, Tyr1138 is essential for activ-
ation of STAT1 and STAT3 [99,100]. The presence of Tyr1077 as
c© 2006 Biochemical Society
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Figure 3 Mechanisms of JAK/STAT activation through OB-Rb
Upon leptin (L) binding, a conformational change takes place (A) that allows juxtaposition of JAKs, which then become activated and are able to tyrosine-phosphorylate other JAKs and tyrosine
residues on the receptor (B). Activation of JAK2 occurs by transphosphorylation and subsequent phosphorylation of tyrosine residues in the cytoplasmic region of the receptor. Phosphorylation of
Tyr1138 allows association of STATs, which then become substrates of receptor-associated JAKs. Phosphorylation of STATs leads to their dissociation from the receptor and the formation of active
dimers (C), which translocate to the nucleus to regulate gene expression, binding to the promoter regions of target genes (D).
the only intracellular tyrosine residue was sufficient to induce
tyrosine phosphorylation of STAT5 and to stimulate STAT5-
driven reporter gene activity in vitro [99]. The critical role of
Tyr1138 was elegantly shown in mice by replacing this residue
with a serine residue [104]. Interestingly, these mice (LeprS1138)
are unable to activate STAT3, thus enabling the disentanglement
of the divergent contributions of the individual STATs to the
different biological roles. LeprS1138 homozygous mutants were
hyperphagic and obese, like db/db mice [104]. Nonetheless,
LeprS1138 homozygotes were less hyperglycaemic than db/db mice,
reached normal sexual development and fertility, and attained a
normal body length. Hypothalamic melanocortin expression was
present in both mutants. However, the increased NPY (neuro-
peptide Y) expression of db/db rodents was not observed in
LeprS1138 homozygotes [104]. These observations, together with
other findings, suggest that STAT3 signalling participates in
energy homoeostasis through the melanocortic/melanocortinergic
pathway, while the control of hypothalamic NPY expression,
linear growth, glycaemia and reproduction are attained via
STAT3-independent pathways [104–107].
Receptor mutants have shown further that lack of Tyr1138 abro-
gates STAT3 signalling by OB-Rb [57,58,76,97]. Cumulative
evidence shows that the JAK/STAT pathway of cytokine signalling
is under the negative-feedback control of SOCS (suppressors of
cytokine signalling) proteins [45,108]. Members of the SOCS
family, which contain an SH2 domain, are induced by a variety of
cytokines, acting as a negative regulator of their signalling. Leptin
has been reported to induce SOCS3 expression [45,98,109–
112]. Initial work showed that Tyr985 of OB-Rb and homol-
ogous sites on related receptors represents a high-affinity binding
site for SOCS3 during signalling by IL-6 receptor family mem-
bers and that this site is critical for signalling inhibition by
SOCS3 [98,101,102,111,113]. However, a more recent study has
provided evidence that Tyr985 is not required for the attenuation
of JAK2 and ERK phosphorylation during prolonged signalling
by the intracellular domain of OB-Rb [114]. Thus Tyr985 is not
necessary for the SOCS3-mediated blockade of JAK2 tyrosine
phosphorylation, suggesting the existence of multiple binding
sites for SOCS3 within activated cytokine receptor complexes
[115]. Brief leptin treatment (30 min) has been shown to stimu-
late the phosphorylation of STAT3, which peaked after 30–
60 min of stimulation, declined to approx. 80% of these levels
after 4 h, and remained at approx. 60% of peak levels after 24 h
of stimulation [114]. In contrast, JAK2 tyrosine phosphorylation
is more transient, declining rapidly to 40–50% of peak levels at 1–
4 h of stimulation and to below 30% after 8–24 h. Similarly, ERK
phosphorylation declined to 20–30% after peaking following
2–4 h of treatment and decreased further to 0–5% of peak
values when 4–8 h had elapsed [114]. The biphasic activation of
ERK exhibits an initial peak of activity between 5 and 10 min
of activation, followed by a maintained activation from 10 min on-
wards. SOCS3 protein was undetectable before stimulation,
whereas Western blotting was able to detect the induction of
SOCS3 protein in cell lysates after 8 h of treatment [114].
Endogenous SOCS3 expression inhibits tyrosine phosphoryl-
ation of OB-R, thus providing an important feedback mechanism
for receptor signalling at the transcriptional level [111]. Moreover,
changes in SOCS3 expression have been postulated to underlie the
phenomenon of leptin resistance [112]. Although it is now clear
that SOCS3 overexpression is able to inhibit multiple aspects
of signalling by the intracellular domain of OB-Rb and other
receptors, it had not been shown that SOCS3 itself does actually
mediate feedback inhibition of OB-Rb signalling. RNAi (RNA
interference)-mediated knockdown of SOCS3 (but not SHP-2)
c© 2006 Biochemical Society
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Figure 4 Proposed model for the participation of SOCS3 in leptin resistance
During prolonged receptor stimulation by leptin (L), the inhibition of JAK2 and ERK phosphorylation is mediated by SOCS3 independently of Tyr985 of OB-Rb.
expression increased the tyrosine phosphorylation of JAK2 and
STAT3 [114]. The researchers provided evidence, for the first
time, that knockdown of SOCS3 not only acutely enhanced ERK
phosphorylation, but also blocked the attenuation of this signal
after prolonged receptor stimulation. Therefore it is plausible that
the Tyr985-independent, Tyr1138-dependent feedback inhibition of
ERK signalling, and probably JAK2, relies on accumulation
of SOCS3 following extended stimulation of the intracellular
domain of OB-Rb [112,114]. Based on these findings, a model
is put forward whereby STAT3 signalling by OB-Rb mediates
critical effects of leptin on food intake and body mass control, at
the same time as mediating a feedback inhibition of the signalling
of the receptor during prolonged stimulation via induction of the
expression of SOCS3 (Figure 4). The participation of SOCS3 in
the negative-feedback mechanism of leptin signalling has been
proposed to underlie the development of leptin resistance in
relation to the hyperleptinaemia observed in the context of the
majority of obesity cases [101]. The relevance of OB-Rb-induced
SOCS3 accumulation in the sensitivity to the biological effects
of the hormone has been shown further by the fact that SOCS3
deficiency elevates leptin sensitivity and confers resistance to diet-
induced obesity [116,117].
Another negative regulator of leptin signalling is represented by
PTP1B (protein tyrosine phosphatase 1B), which has been shown
to regulate leptin signal transduction both in vivo and in vitro,
primarily via dephosphorylation of JAK2 [24,45,118–120].
PTP1B has been reported to be a physiologically important nega-
tive regulator of insulin signalling [24,121,122]. Mice lacking
PTP1B were resistant to developing diet-induced obesity and did
not exhibit hyperphagia despite a clear hypoleptinaemia. Under
physiological circumstances, the effects of PTP1B are likely to
be exerted via central and peripheral actions. Consistent with the
involvement of PTP1B in leptin-dependent signalling pathways,
administration of leptin to PTP1B-knockout mice was followed
by a hypersensitivity to the physiological effects of the hormone
in body mass control [24,118].
MAPK (mitogen-activated protein kinase) cascade
The ERK members of the MAPK family are components of the
well-defined Ras/Raf/MAPK signalling cascade and become ac-
tivated by a wide range of stimuli, including leptin (Figure 5). The
MAPK pathway can be stimulated by either OB-Ra or OB-Rb,
although to a lesser extent by the former [80,101]. Although the
distal portion of OB-R is not essential for MAPK signalling,
the intact intracellular part of the long receptor is needed to
achieve maximal activation. This is based on the fact that leptin is
able to trigger the MAPK cascade in two different ways, i.e. via
tyrosine phosphorylation of JAK2 receptor-associated activation,
or independently of receptor phosphorylation [60,80]. None-
theless, in both pathways, downstream signalling requires an
intact catalytic domain of SHP-2. It has been reported that a lack
of phosphatase activity causes a failure of ERK phosphorylation
[102]. Although it has not been completely elucidated which
molecules are involved in transmitting the leptin signalling, activ-
ated MEKs (MAPK/ERK kinases) phosphorylate ERKs, leading
finally to the expression of specific target genes, such as c-fos and
egr-1, that participate in cell proliferation and differentiation.
Activation of the MAPK signalling pathway has been observed
both in vivo and in vitro, as well as centrally and peripherally. In
precursor cells of the osteoblastic lineage, leptin has been demon-
strated to induce apoptosis through the MAPK cascade via
ERK1/2 activation of cytosolic phospholipase A, which in turn
leads to cytochrome c release and finally to caspase 3 and caspase
9 induction [123]. In monocytes, leptin activates the promoter
of IL-1Ra (IL-1 receptor antagonist) through p42/44 MAPK
and a composite NF-κB (nuclear factor κB)/PU.1 binding site
[124]. A further study has revealed that leptin stimulates nitric
oxide synthase activity in white adipose tissue through a complex
mechanism that involves PKA (protein kinase A) and p42/44
MAPK [125].
A wide range of stimuli, including osmotic stress, heat shock
and cytokines, among others, activate another member of the
c© 2006 Biochemical Society
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Figure 5 The MAPK pathway in leptin signalling
The ERK members of the MAPK family are components of the well-defined Ras/Raf/MAPK signalling cascade and have become activated by leptin (L). For more detailed information, see the text.
DAG, diacylglycerol; Grb-2, growth factor receptor binding-2; PI3, PtdIns(3,4,5)P3; PLC, phospholipase C; SOS, son of sevenless.
MAPK family, namely p38 MAPK [72]. Leptin has been shown
further to increase the phosphorylation of p38 MAPK in mono-
nuclear cells, as well as in L6 muscle cells, most probably not
as a direct effect, but by reducing insulin-stimulated p38 MAPK
phosphorylation [126]. Leptin shares with other cytokines, growth
factors and stressors the ability to activate the stress-activated
protein kinase, JNK (c-Jun N-terminal kinase). In this respect,
leptin reportedly enhances TNFα (tumour necrosis factor α)
production via p38 and JNK MAPK in LPS (lipopolysaccharide)-
stimulated Kupffer cells [127]. In vascular smooth muscle cells,
leptin induces hypertrophy via p38 MAPK [128], indicating
the potential relevant role of this hormone in cardiovascular
physiology and an impact on vascular remodelling [129]. Overall,
a definitive picture of leptin signal transduction, including up-
stream activators and downstream targets of the p38 and JNK
MAPK pathways, remains to be completely disentangled. With
regard to the downstream targets, the regulation of NF-κB appears
as a clear candidate since this essential transcription factor is
known to play a pivotal role in the transcriptional regulation of
pro-inflammatory cytokines such as TNFα and IL-1β.
The PI3K (phosphoinositide 3-kinase)/PDE3B
(phosphodiesterase 3B)/cAMP pathway
PI3K activity represents a key target regulated by a broad spec-
trum of ligands, with insulin requiring special mention. In fact,
most insulin-dependent actions involve PI3K activation, making
this a relevant point of cross-talk between the insulin and leptin
signalling pathways [32,60,130,131]. PI3K products typically
stimulate protein kinases such as Akt (protein kinase B) and
PKC (protein kinase C) isoforms [72]. Leptin reportedly acts
through some of the components of the insulin signalling cascade
(Figures 6 and 7). The binding of insulin to its receptor recruits
several IRSs (insulin receptor substrates) that are tyrosine-phos-
phorylated by the intrinsic kinase activity of the receptor. In
turn, phosphorylation of IRSs increases their affinity for binding
other signalling molecules, thus initiating further steps of the
pathway. IRS proteins exert PI3K activation via association with
its regulatory subunit, p85, and increasing the activity of the
catalytic domain. The stimulation of PI3K leads to activation
of PtdIns(3,4,5)P3-dependent serine/threonine kinases such as
PDK1 (phosphoinositide-dependent kinase 1), which is able to
activate Akt, a further serine/threonine kinase representing a
key step in subsequent downstream signalling. In the central
nervous system, as well as in, for instance, adipose tissue,
pancreas and liver, leptin has been shown to induce an insulin-
like signalling pathway involving PI3K-dependent activation
of PDE3B and eventual cAMP reduction [132–134]. Indirect
evidence for a plausible participation of the IRS/PI3K cascade in
leptin action came from the phenotype of IRS2-null mice, which
exhibited hyperphagia and a hypometabolic state in the presence
of increased adiposity and hyperleptinaemia, but not as marked as
for db/db animals [58]. Leptin has been shown to stimulate IRS2-
mediated hypothalamic PI3K activity, while pharmacological
blockade of PI3K abrogated the leptin-induced hyperpolarization
of NPY/AgRP (agouti-related peptide) neurons, thus blocking
the anorectic effect of leptin [58,135]. Interestingly, inhibition of
PI3K is not able to influence the anorectic effect of melanocortin
agonists operating downstream of OB-Rb. Moreover, PI3K
activity is also required for leptin-mediated sympathoactivation
[136]. Although the precise contribution of insulin- versus leptin-
induced PI3K stimulation to actual signalling remains difficult
to dissect, overall findings indicate that the PI3K/PDE3B/cAMP
pathway interacting with the JAK2/STAT3 cascade constitutes a
critical component of leptin signalling in the hypothalamus [45].
However, results are inconsistent in different cell lines and the
nature of the leptin–insulin cross-talk mechanisms operating in
each cell type may exhibit certain particularities. Thus leptin itself
has no direct effect on the insulin pathway in a well-differentiated
hepatoma cell line, while pre-treatment with leptin transiently
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Figure 6 The PI3K/PDE3B/cAMP cascade
Stimulation of the PI3K pathway by leptin (L) represents a key cascade to exert several different effects of the hormone at multiple sites. For more detailed information, see the text. C/EBP,
CCAAT/enhancer-binding protein; eNOS, endothelial nitric oxide synthase; GSK3, glycogen synthase kinase 3.
Figure 7 Cross-talk of leptin signalling with insulin-induced pathways
Leptin (L) receptor (OB-Rb) activation acts through some of the components of the insulin signalling cascade, recruiting several IRSs. PIP2, PtdIns(4,5)P2, PIP3, PtdIns(3,4,5)P3.
enhances insulin-induced IRS1 phosphorylation and its associ-
ation with p85. Leptin administration results further in Akt
phosphorylation, without affecting insulin-induced phosphoryl-
ation. Furthermore, leptin alone exerts a less pronounced effect
on GSK3 (glycogen synthase kinase 3) serine-phosphorylation
than insulin [137]. In C2C12 muscle cells, leptin reportedly
activates PI3K via JAK2- and IRS2-dependent pathways [89]. In
these myotubes, leptin also recruits GLUT4 to the cell surface
and stimulates glucose transport. This effect can be blocked
by wortmannin, which can inhibit both PI3K and MAPK [60].
Leptin-induced stimulation of PI3K has been observed to affect
hormone-sensitive lipase activity in macrophages, which can be
blocked using PI3K inhibitors [138]. In pancreatic β-cells, leptin
participates in the regulation of PDE3B, decreasing cAMP levels
c© 2006 Biochemical Society
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Figure 8 Signalling pathways reported to be regulated by leptin
The schematic diagram summarizes the numerous and diverse pathways in which leptin has been shown to be involved. DGK, diacylglycerol kinase; PG, prostaglandin; PLC, phospholipase C; ROS,
reactive oxygen species. Modified from Cellular Signalling, vol. 14, Sweeney, G., ‘Leptin signalling’, pp. 655–663, c© 2002, with permission from Elsevier.
and inhibiting the insulin secretion stimulated by glucagon-like
peptide-1 [133].
A signalling pathway divergent from activated PI3K results in
the induction of K+/ATP channels, which trigger a hyperpolariz-
ation of the cell membrane. This intracellular mechanism has been
observed to take place in insulinoma cells, isolated pancreatic
islets and glucose-sensitive hypothalamic neurons [60,72]. Appar-
ently, Akt, p70S6K or MAPK downstream cascades stimulated
by insulin are not used by leptin in this alternative pathway.
The most probable candidate is PtdIns(3,4,5)P3, which leads to
disruption of actin filaments, the last known step for K+/ATP
channel enhancement by leptin [60,139].
Analogous to other dual actions of leptin, the hormone is able
to trigger both stimulatory and inhibitory effects on PKC. The
release of insulin from pancreatic islets of ob/ob mice in response
to PKC stimulation has been shown to be blunted by leptin [72].
It has been observed further that the ability of leptin to lower
glucose-mediated insulin secretion was correlated with its capa-
city to decrease the activity of Ca2+-dependent PKC. There is also
evidence suggesting that leptin action in pancreatic islets may
block the PKC-regulated component of the phospholipase C–PKC
signalling system that is involved physiologically in insulin se-
cretion [72].
AMPK (5′-AMP-activated protein kinase)
It has been clearly established that leptin stimulates fatty acid
oxidation, thereby exerting a protective effect against lipotoxicity
in non-adipose tissues [11]. However, the signalling elements
counteracting lipotoxicity were not fully understood until some
years ago when a novel pathway participating in leptin’s action
on metabolism was identified [140]. Leptin was observed to
selectively activate the α2 catalytic subunit of AMPK in skeletal
muscle, which stimulates fatty-acid oxidation by blocking the
effect of ACC (acetyl-CoA carboxylase). AMPK represents a
heterotrimeric enzyme that functions as a ‘fuel gauge’ to monitor
cellular energy status [141,142]. AMPK regulates food intake
by responding to hormonal and nutrient signals in the hypo-
thalamus [141]. Activation of AMPK represents a signal to shut
down anabolic pathways and to promote catabolic processes in
response to a decrease in the ATP/AMP ratio by phosphorylating
key enzymes of intermediary metabolism. In parallel with AMPK
activation, leptin suppresses ACC activity, thereby stimulating
β-oxidation in muscle by disinhibiting CTP1 (carnitine palmitoyl-
transferase 1). After leptin treatment, the increased AMP levels
activate AMPK after only 15 min. This rapid response relies on a
direct effect following leptin binding to OB-Rb in skeletal muscle,
although the exact post-receptor activation needs to be elucidated
fully. It is not yet clear how leptin increases AMP levels and
activates AMPK when targeting muscle cells directly. Leptin
is also able to cause a similar effect, although with a time-lag,
by acting through the α-adrenergic system as a result of hypo-
thalamic stimulation [60,142–144]. The direct activation of
AMPK by leptin also explains, at least in part, the findings that
leptin increases both in vitro and in vivo glucose uptake and meta-
bolism.
OTHER SIGNALLING CASCADES ACTIVATED BY LEPTIN
Leptin has been discovered to act as a multifunctional cytokine in
all tissues, being involved in many cellular functions throughout
the whole body. To develop its widespread effects, leptin interacts
with many signalling factors, cross-talking with different signal
transduction pathways through its ubiquitous receptors (Figure 8).
The main cascades activated by leptin have been described above.
However, there are several other signalling events in which leptin
has been observed to be involved. Some of them have been clearly
established, while others are only beginning to unfold.
The relevance of leptin in the pathogenesis of cardiovascular
complications associated with obesity is being extensively studied
[41,145]. Taking into consideration the morphological and
physiological resemblance between NO (nitric oxide) and leptin,
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the potential functional relationship between them has been
established [2]. Leptin administration has been shown to increase
serum NO concentrations [29]. In addition, NO has been observed
to facilitate leptin-induced lipolysis [146]. As regards blood press-
ure homoeostasis, leptin has been shown to be involved in vascular
tone control by simultaneously producing a neurogenic pressor
action and an opposing NO-mediated depressor effect [29]. Sub-
sequent studies have disentangled further the participation of
leptin in blood pressure regulation, showing that the inhibition
of angiotensin II-induced intracellular calcium increase and vaso-
constriction elicited by leptin is via an NO-dependent mechanism
[147]. Moreover, it has been shown recently that the leptin-
induced NO production in white adipocytes is mediated through
PKA and MAPK activation [125].
Among the extraneural effects of leptin, one of the first to be
identified was the participation of the hormone in angiogenesis
[27]. It was observed that endothelial cells express functionally
competent OB-R. Leptin has been shown to cause cultured endo-
thelial cells to aggregate, form tubes and display a reticular array
reminiscent of tissue vasculature. The effects, tested both in vitro
and in vivo, indicate that leptin contributes to the promotion of
angiogenic processes [27,148].
The angiogenic effect of leptin suggests several intriguing pos-
sibilities. One is that leptin contributes to the formation of the new
blood vessels needed when the fat mass increases in volume, thus
driving the blood vessels to match the amount of fat. The hormone
produced by adipocytes not only is secreted into the bloodstream,
but also may act locally upon endothelial cells in a paracrine
fashion, assuring an appropriate balance between blood supply
and fat depot size [9]. However, it does not appear to be essential
for this function, because the enormous fat depots in mutant mice
that completely lack leptin manage to recruit an adequate blood
supply. Cell growth, cell migration and angiogenesis are normal
biological processes hijacked by tumour cells to promote tumour
proliferation and invasion. Being an angiogenic factor, leptin
may be deployed by some cancers to recruit blood vessels. Both
primary tumour growth and the formation of metastasis depend
on the establishment of new blood vessels. It is interesting to
note that rat insulinoma-derived pancreatic β-cells express a func-
tional leptin receptor that mediates a proliferative response [149].
Analogously, OB-Rs have been shown to be expressed in human
colon cancer cell lines as well as in human colonic tissue [150].
In addition, stimulation of colonic epithelial cells with leptin has
been reported to increase proliferation both in vitro and in vivo.
To maintain oxygen homoeostasis, the mammalian microvascu-
lature undergoes dramatic reorganization in order to supply oxy-
gen and nutrients to hypoxic tissues. Several transcription factors
operate to promote angiogenesis, sensing the environmental
cues that drive the process. One of the factors that stands out
is HIF-1α (hypoxia-inducible factor 1α), which acts as a master
transcription switch for the regulation of oxygen homoeostasis
[151]. In physiological circumstances, HIF-1α is targeted for
ubiquitination and rapid degradation. Under hypoxic conditions,
HIF-1α is activated through PI3K/Akt and MAPK/ERK path-
ways. HIF-1α then translocates to the nucleus and binds to the
promoters of genes involved in angiogenesis, such as the gene en-
coding VEGF (vascular endothelial growth factor) [151]. Interest-
ingly, the JAK2/STAT5 pathway has been shown to be in-
volved in mediating processes related to angiogenesis [152].
A key molecule in this axis is VEGF, whose tyrosine kinase
receptor has been demonstrated to exhibit specific STAT activ-
ation capabilities. Consistent with their complementary role in
angiogenesis, VEGF and STATs are both sensitive to diverse cel-
lular stressors, including hypoxia, which is a well-known stimu-
lator of leptin synthesis and secretion [9]. Hypoxia markedly
enhances the expression of leptin and VEGF as well as stimulating
HIF-1α [153]. In fact, HIF-1α has been shown to transactiv-
ate the leptin gene promoter and to act synergistically with insulin,
regulating, via different transcriptional elements, the human leptin
promoter [154,155]. The relevance of the VEGF/leptin/HIF-1α
axis merits detailed consideration as regards processes involving
neovascularization, such as tumour growth, diabetic retinopathy,
adipose mass enlargement, atherosclerosis and liver regeneration.
The impact of leptin on several equally relevant signalling
pathways extends also to Rho family GTPases, which are
implicated in numerous cellular processes, such as apoptosis and
regulation of the actin–myosin cytoskeleton [72]. Remodelling of
the actin cytoskeleton represents a plausible key element in the
promotion of invasiveness of colon epithelial cells in response
to leptin, since leptin’s effect was potentiated by constitutively
active RhoA and decreased by dominant-negative RhoA, Rac1 or
the p110α catalytic subunit of PI3K [72]. There are many other
signalling molecules that interact with leptin at different levels
that might deserve more careful consideration, e.g. leptin’s par-
ticipation in the production of reactive oxygen species, stimu-
lation of prostaglandins, binding to diacylglycerol kinase-ς , activ-
ation of the p90 ribosomal protein S6 and p70S6K, as well as
catecholamine secretion [72,126,156–159].
PERSPECTIVES
Leptin has contributed significantly to broadening our understand-
ing of the intracellular signalling cascades involved in the develop-
ment of a myriad of neuroendocrine functions. The almost ubi-
quitous distribution of leptin receptors in peripheral tissues has
provided a fertile area for investigation, and a more dynamic
view of leptin has started to unfold. The notion of a mere lipo-
static factor has been surpassed by that of a pleiotropic leptin
system. The ability of leptin to activate several different pathways,
apart from its central role in energy homoeostasis, has been
uncovered. However, many keys remain to be deciphered with
regard to leptin production, rhythmicity, transport, intracellular
pathways and their teleological meaning. The relative contribution
of the complex network of signalling pathways that participate in
the periphery remains to be determined fully. It will be interesting
to gain more insight into how the different pathways down-
stream of leptin are integrated in the diverse peripheral tissues
[160,161]. It will be also worthwhile to focus on how leptin
signalling integrates with the intracellular cascades activated by
other more recently discovered hormones, adipokines, receptors,
channels and peptides both in the central nervous system as well
as in the periphery, such as resistin [162,163], ghrelin [164],
adiponectin [165], peptide YY3−36 [166], visfatin [167], vaspin
(visceral adipose tissue-derived serine protease inhibitor) [168],
endocannabinoids [169,170], aquaporin-7 [171] and FAT-ATTAC
(fat apoptosis through targeted activation of caspase 8) [172]. In
addition, major advances in the molecular mechanisms underlying
leptin resistance and its consequences are to be expected. The
diverse mechanisms that link leptin signalling in the brain, as
well as in peripheral tissues, will clarify the pathogenesis not
only of obesity but also of other associated diseases. To close the
gaps or to complete the signalling network map for leptin’s actions
will provide valuable information with regard to the knowledge
of the complex signalling patterns characteristic of cell biology,
as well as opening up potentially effective ways for therapeutic
manipulation. Undoubtedly, given leptin’s versatile and ever-
expanding list of activities and involvement in signalling cascades,
additional and unexpected consequences of leptin action are sure
to emerge. The intense investigations under way on many different
frontiers of leptin research will add more information to the
c© 2006 Biochemical Society
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already large body of knowledge. Disentangling the biochemical
and molecular mechanisms in which leptin is involved represents
an exciting challenge ahead.
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